.jetcityimage/iStock Content via Getty Images Morgan Stanley has actually chosen Eli Lilly (NYSE: LLY) as its best biopharma selection for 2025 and also rated one more 9 names in the room as obese. The expenditure banking company pointed out in a keep in mind that it remains to strongly believe “diabesity is actually set to end up being.